Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04226352 · ClinicalTrials.gov registry record · Phase 1
Three Dosing Regimens of Dextromethorphan (DXM) Reportedly Used in Major Depressive Disorder
A Phase 1 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT04226352: Completed Phase 1 study, sponsored by Johns Hopkins University.
NCT04226352 is a Phase 1 study that has completed, run by Johns Hopkins University. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04226352, a Phase 1 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is an open-label dosing pilot study of 15 patients aged 18-50 years of age with diagnoses of Major Depressive Disorder (MDD) randomized to 1 of 3 treatment arms. The study will consist of a screening evaluation performed within the course of 2 weeks, followed by an active treatment period of 28 days where treatment arm 1 will take a supervised dose of 300mg DXM every 14 days for 28 days, treatment arm 2 will take the FDA approved maximum daily ingestion for cough (60mg DXM) daily for 28 days, and treatment arm 3 will take 1 supervised dose of 300mg DXM and 60mg for the remaining 28 days. After the active treatment period, subjects will be followed for 65 days with safety and psychiatric assessments at designated timepoints.
Interventions
- DRUG Dextromethorphan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2020-03-15 |
| Est. Completion | 2021-12-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04226352
The ClinicalTrials.gov registry entry for NCT04226352 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dextromethorphan is the first listed.
NCT04226352 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04226352 about?
NCT04226352 is a clinical study titled "Three Dosing Regimens of Dextromethorphan (DXM) Reportedly Used in Major Depressive Disorder". This is an open-label dosing pilot study of 15 patients aged 18-50 years of age with diagnoses of Major Depressive Disorder (MDD) randomized to 1 of 3 treatment arms. The study will consist of a screening evaluation performed within the course of 2 weeks, followed by an active treatment period of 2...
What is the current status of trial NCT04226352?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2020-03-15. Estimated completion is 2021-12-07.
What interventions are being tested in trial NCT04226352?
The interventions under investigation include: Dextromethorphan (DRUG).
Who is sponsoring clinical trial NCT04226352?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.